Cardiometabolic medicine is gaining momentum as a subset of both endocrinology and cardiology specialties with combined cardiometabolic services forming to address the significant burden of cardiometabolic disease in various centres. There have been multiple recent advances in the diagnosis and treatment of lipid disorders with significant improvements in both lipid concentrations and cardiovascular events demonstrated in multiple clinical trials. Awareness of inherited lipid disorders is growing, particular for familial hypercholesterolaemia (FH), which is the most prevalent autosomal co-dominant disorder of low-density lipoprotein catabolism that is present in ~1:300 people in the population. However, further work is required as currently less than 10% of people with FH are current identified and treated. I will outline the benefits of availability of genetic testing for FH and recent guidelines. I will also describe emerging specific lipid / lipoprotein lowering therapies including monoclonal antibodies and antisense oligonucleotides.